JPY3,940.00
1.92% today
Tokyo, Feb 05, 07:15 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY3,935.00
-365.00 8.49% 1M
-960.00 19.61% 6M
-417.00 9.58% YTD
-642.00 14.03% 1Y
+1,574.50 66.70% 3Y
+1,301.67 49.43% 5Y
+3,344.17 566.01% 10Y
Tokyo, Closing price Wed, Feb 05 2025
-82.00 2.04%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY7.40t
Enterprise Value JPY6.82t
P/E (TTM) P/E ratio 31.13
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.80
P/S ratio (TTM) P/S ratio 4.12
P/B ratio (TTM) P/B ratio 4.65
Dividend yield 1.49%
Last dividend (FY25) JPY60.00
Revenue growth (TTM) Revenue growth 19.46%
Revenue (TTM) Revenue JPY1.80t
EBIT (operating result TTM) EBIT JPY237.17b
Free Cash Flow (TTM) Free Cash Flow JPY-88.15b
Cash position JPY682.15b
EPS (TTM) EPS JPY129.03
P/E forward 33.08
P/S forward 4.02
EV/Sales forward 3.70
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a DAIICHI SANKYO forecast:

17x Buy
100%

Analyst Opinions

17 Analysts have issued a DAIICHI SANKYO forecast:

Buy
100%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,795,986 1,795,986
19% 19%
100%
- Direct Costs 426,022 426,022
2% 2%
24%
1,369,964 1,369,964
26% 26%
76%
- Selling and Administrative Expenses 655,257 655,257
28% 28%
36%
- Research and Development Expense 410,753 410,753
15% 15%
23%
303,954 303,954
41% 41%
17%
- Depreciation and Amortization 66,788 66,788
2% 2%
4%
EBIT (Operating Income) EBIT 237,166 237,166
58% 58%
13%
Net Profit 245,769 245,769
32% 32%
14%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Sunao Manabe
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today